International Clinical Trial: A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA(R) (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739589) titled 'A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA(R) (Levonorgestrel and Ethinyl Estradiol) Transdermal System' on July 28.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: Insud Pharma

Condition: Residual Drug Amount of EE and LNG

Intervention: Drug: Twirla(R) (Levonorgestrel/Ethinyl Estradiol) Transdermal System

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: October 25, 2021

Target Sampl...